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Background Older people with intellectual disabilities (ID) receive anticholinergic drugs but no studies to date 
have investigated cumulative anticholinergic exposure and its effects in adults with ID. 
Aim: To determine the cumulative exposure to anticholinergics and the factors associated with high exposure. 
Methods A modified anticholinergic burden score (ACB) was calculated for a representative cohort 
(2009/2010) of 736 people over 40 years with ID and associations with demographic and clinical factors 
assessed. 
Results Age over 65 years was associated with higher exposure (ACB 1-4- OR 3·28; 95% CI 1·49-7·25, ACB 
5+- OR 3·08; 95% CI 1·21-7·63), as was a mental health condition (ACB 1-4- OR 9·79; 95% CI 5·63-17·02, 
ACB 5+- OR 23·74; 95% CI 1·29-45·83). Day time drowsiness was associated with higher ACB (p<0·001) and 
chronic constipation reported more frequently (26·6% ACB 5+ vs 7·5% ACB 0) (p<0·001). 
Conclusions Older people with ID and with mental health conditions were exposed to high anticholinergic 
burden. This was associated with daytime dozing and constipation.  
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Introduction 
Many medicines used to treat conditions prevalent in older people possess anticholinergic (AC) activity and they 
may produce central and peripheral side effects - sedation, confusion, dry mouth, adverse dental outcomes and 
constipation (1). The risk of adverse outcomes including hospitalisation and falls increases with increasing 
anticholinergic exposure. (1, 2) Frail, older people are particularly vulnerable to anticholinergic adverse effects 
due to high probability of exposure to treat multiple conditions, and increased age-related sensitivity to 
anticholinergic-related cognitive adverse effects (3). Furthermore, medical problems prevalent in older people 
such as constipation, sleep difficulties and dementia may be worsened by use of anticholinergics.(4) 
Consequently, anticholinergic medications are considered potentially inappropriate in older populations, 
particularly those with dementia who have limited cognitive reserve. (3, 5) A systematic review examining 
associations between drugs with anticholinergic effects and adverse outcomes in older adults carried out by 
Ruxton and colleagues concluded that exposure to individual medicines with AC effects or increased overall AC 
exposure may increase risk of falls, cognitive impairment and all cause mortality. (6) In those over 65 years of 
age one recent study has shown associations with dementia and cognitive impairment. (7) 
 
People with intellectual disabilities (ID) continue to have a shorter life expectancy compared to the 
general population, are at increased risk of mortality from preventable or treatable illnesses,(8) and experience 
health inequities, including barriers to accessing primary care.(9) They experience up to 2.5 times the health 
problems (10) and higher incidence of morbidities such as dental disease, eye disease, epilepsy and dementia. (11, 
12) Dual diagnosis is common, with one study reporting 41% of adults with ID with mental illness, (13) which 
increases the likelihood of polypharmacy. Higher use of antipsychotics and other psychotropics prescribed to 
manage mental health conditions and challenging behaviours is a concern (14-16) and may confer additional risk 
as organic brain dysfunction may lead to idiosyncratic responses to drugs. (17) Drug-induced anticholinergic 
activity is thought to be additive; the overall burden of anticholinergic drugs determining the risk of adverse 
effects. (18) People with ID may be at  additional risk of experiencing the “prescribing cascade” as for example, 
the high prevalence of antipsychotic use may lead to the prescribing of anticholinergics for movement disorders 
(extrapyramidal symptoms; ATC N04A), a practice no longer recommended in older people (5). (6) 
Anticholinergic (AC) effects may be misattributed to a consequence of the normal ageing process and drugs with 
AC properties may be a cause of unrecognised adverse drug reactions (ADRs). (19)  
 
People with ID receive a variety of different medicines with anticholinergic activity and scales which capture 
cumulative burden are needed to stratify risk. The Anticholinergic Cognitive Burden (ACB) scale is one such 
scale that computes a total score of drugs to determine individual anticholinergic burden. (1) The ACB scale 
identifies the burden of anticholinergic negative effects on cognition of medications (prescribed and over the 
counter)-; drugs with no AC effects score 0, drugs with possible AC effects score 1, drugs with definite cognitive 
anticholinergic effects score 2 or 3. (1) In one study an ACB score of 5 or more was associated with an Mini 
Mental State Examination (MMSE) score of 1 point lower compared to an ACB score of 0.(20) It also found the 
largest effect on cognitive decline was observed in people with mild dementia (MMSE 26 to 30). The ACB scale 
has been demonstrated to have predictive validity, with higher ACB scores associated with adverse clinical 
outcomes.(21) 
Given evidence in the general older population of the risks associated with anticholinergic exposure and of frailty, 
cognitive decline and adverse effects we hypothesised that adverse effects would be associated with exposure to 
a high anticholinergic load in older people with ID. 
Our objectives were;  
(i) to determine each individual’s cumulative exposure to anticholinergic medications by using the ACB scale;  
(ii) to describe the pattern of anticholinergic medication use in relation to demographic and clinical characteristics 
and the most frequently reported therapeutic classes contributing to the anticholinergic burden; 
(iii) to examine factors associated with higher anticholinergic burden exposure; 
(iv) to explore the relationship between anticholinergic burden scores and indicators of central and peripheral 
anticholinergic adverse effects. 
 
 
Methods 
Study Design 
Medication data for this study was drawn from Wave 1 (2009/2010) of the Intellectual Disability Supplement to 
the Irish Longitudinal Study on Ageing (IDS-TILDA), which contains a nationally representative sample of 753 
persons with an ID, aged between 41 and 90 years (figure 1).(22) IDS-TILDA is a longitudinal study of older 
adults with ID and has been described in detail elsewhere.(22, 23) Age 40 years and over was selected to reflect 
the lower longevity of people with ID and their earlier onset of chronic disease, for example dementia (24). (25). 
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This would also ensure that there would be sufficient subjects for future waves of data collection and provide 
opportunities to offer insights into ageing for those who may age prematurely. Everyone included in the study 
was registered on the NIDD, and therefore had an intellectual disability. The person’s level of ID was checked 
and confirmed from case notes at the time of the face-to face interview. The STROBE (The Strengthening the 
Reporting of Observational Studies in Epidemiology) reporting guidelines for cross-sectional studies was 
utilised.(26) Ethical approval for the study was received from the Faculty of Health Sciences Trinity College 
Dublin and 138 Intellectual Disability Service Providers, and all participants and/or proxies as appropriate 
provided informed consent to partake in the study.  
 
ADD FIGURE 1 HERE 
Medication Exposure Measures 
Participants/proxies were asked “Can you tell me what medications (including prescribed and over the counter, 
herbal medicines) you take on a regular basis – like every day or every week?” in the pre-interview 
questionnaire. (22) The pre-interview questionnaire was sent to participants and/or proxies one week in advance 
of the face to face interview to give them time to check patient records or charts to record the medicines they 
were taking. This information was then cross-checked by interviewers at the time of interview, by asking if the 
list they had provided in the pre-interview questionnaire included all of their medicines, and where necessary 
checking patient files if they had permission.   
Medicines were recorded by brand or generic name, including prescription and non-prescription and over the 
counter, and all data was anonymised. Medications were coded using the World Health Organization (WHO) 
Anatomical Therapeutic Chemical (ATC) classification system. (27) Two pharmacists (MO’D, JP) independently 
reviewed and confirmed medication entries.  
 
Measuring Exposure to Anticholinergic Medications 
The dependent variable was participants’ Anticholinergic Burden Score calculated using the updated 2012 
Anticholinergic Cognitive Burden (ACB) Scale.(28) 
In addition, the ACB list was assessed and modified to include drugs with anticholinergic properties taken by 
participants, available in Ireland, but not included in the ACB scale. (20) Two pharmacists (MO’D, IM- who 
developed the original scale) independently consulted standard reference sources, the product characteristics 
(SmPC) information, and the other validated anticholinergic rating scales, to assign a score to other drugs with 
anticholinergic properties available in Ireland but not included in the ACB list; this was based on the approach 
used to develop the original scale The 22 medicines not included in the original ACB list with respective scoring 
are listed in Suppl Table1. Medications with anticholinergic properties which were not available in Ireland and/or 
not present in the dataset were excluded (42 medications).  
We categorised exposure to anticholinergics in three ways; (i) The total Anticholinergic Cognitive Burden (ACB) 
score of each individual, created by summing the score of each possible (ACB1) or definite (ACB2 or 3) 
anticholinergic, (ii) a binary variable; those exposed to any anticholinergic medicine, (ACB score ≥1), and no 
anticholinergic exposure (ACB 0), and (iii) a categorical variable; no exposure to anticholinergic medications 
(ACB 0), ACB score of 1-4 , and ACB score of ≥5), as in previous studies. (20)  
 
Covariates 
Covariates included; gender, age (a categorical variable; 40-49 years, 50-64 years, 65+ years) , level of 
intellectual disability, place of residence (independent, community group home or residential setting), 
Residential settings  were defined as living arrangements where ten or more people share a single living unit or 
where the living arrangements are campus‐based. Community group homes are in community setting with staff 
support for small groups (<10) of people with ID. Other covariates included any dementia (doctor’s diagnosis of 
dementia, organic brain dysfunction, senility or serious memory impairment), polypharmacy (no 
polypharmacy=0-4 medicines), polypharmacy=≥5 medicines). Participants/ proxies reported if the participant 
had ever received a doctor’s diagnosis of 12 chronic health conditions. (23) Dementia, lung disease, stroke, 
cancer and liver disease had insufficient numbers (<5% prevalence) and were excluded from further multivariate 
analysis.  
The relationship between anticholinergic exposure and indicators of anticholinergic adverse effects was examined; 
if the participant had reported fall(s) in the previous year, day-time dozing, constipation or physician diagnosed 
chronic constipation and laxative use. Participants were also divided into those who were dentate or edentulous. 
(29) 
 
Statistical Analyses 
Descriptive statistics (percentages, medians (as the data was not normally distributed), and 95% confidence 
intervals (C.I.s)) described the characteristics of the eligible study population.  
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We used univariate analysis to examine the associations between the dependant (anticholinergic exposure (ACB 
≥1) versus no exposure) and clinical and demographic variables. Here, for categorical variables chi-squared (2) 
tests for independence was used to test for a significant association between the three ACB groupings. For 
continuous variables, a one-way Analysis of Variance (ANOVA) was used to test for a significant difference. 
Multinomial logistic regression identified factors associated with an ACB of 1-4 and an ACB of 5+, with those 
with no AC exposure (ACB 0) as the reference category. All demographic variables were included in the model 
(age, gender, and level of ID). Those with unverified level of ID (n=54) were excluded from regression analyses. 
Those who lived independently or in community group homes were combined as a single group, as the numbers 
in the independent setting with AC exposure were small (n=11). 
Variables with a p value <0·10 in univariate analysis were included in our multivariable model (this p value was 
selected to ensure that important or influential factors were not omitted)(30). All variables were entered into the 
model simultaneously. The model is adjusted for polypharmacy status (polypharmacy versus no polypharmacy), 
with results presented as adjusted Odds Ratios with corresponding 95% CIs.  
Sample size calculation for the logistic regression was based on the guideline of Peduzzi et al. (1996); for a 
minimum number of cases (N) needed for the study; N=10 k/p, where p is the smallest of the proportions of 
negative or positive cases in the population, k the number of covariates (independent variables). (31) For the 
regression model there were 10 covariates and the proportion of negative cases (ACB 0) was 0·284, therefore a 
minimum sample size (N) of 352 was needed. There were 658 cases available for regression analyses, so sample 
size was sufficient.  
The ACB score and anticholinergic adverse effects were explored at univariate level. To control for problems of 
Type I error associated with multiple comparisons a Bonferroni correction was applied,(32) testing six 
associations, with a desired α of 0·05, resulting in α=0·05/6 =0·008. 
Statistical Analyses were carried out using the Statistical Package for Social Sciences, Version 20 (SPSS Inc.). 
 
Role of the Funding Source and Access to Data 
The IDS-TILDA study is funded by the Health Research Board and the Department of Health and Children. The 
lead author (MO’D) received funding for a PhD from the Trinity College Dublin Studentship. The funding body 
did not play a role in the study design, writing of the manuscript. The corresponding author (MO’D) had full 
access to the study data, and had final responsibility to submit for publication. 
 
 
Results 
Of 753 participants, 736 (98%) provided medication use data. Baseline characteristics of our sample are presented 
in Table 1. Mean age of participants was 54·1 years (S.D·8.8, range 41-90 years), with almost half (45·7%) aged 
between 50-64 years. Almost half (46%) of the sample with recorded level of ID (n= 682) reported moderate ID. 
Overall, participants reported a mean (±SD) of 5.7(±4.4) medicines, with 53.7% exposed to polypharmacy (5+ 
medicines).  
In the total sample of 736, no exposure was reported by 214 (29·1%; ACB = 0, while 308 (41·8%) had a score of 
ACB 1-4 and 214 (29·1%) ACB score 5+ (Table 2). Of those reporting medications with ACB ≥1 score (522) half 
(370) received medicines with an ACB score of 2 or 3, and of those (n=370), 42·9% (159) reported concurrent 
use of two or more ACB 2 or 3 drugs. The median (±S·D) total ACB score was 4·0 (±3·0) (range 1-16; N=522).  
There was a significant association between ACB score and reporting mental health conditions (n=706) 
(p<0·001); 46·6% had ACB 5+, and a further 46·7% had a score of 1-4 (p<0·001). 
Similarly level of ID was associated with AC exposure; 36·5% of those with severe/ profound ID had an ACB 
score of 5+, compared to just 19·9% of those with mild ID (n=682, p<0·001) (Table 2).  
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INSERT TABLE 1 HERE, TABLE 2 
In total, 72 different AC medicines were reported in 1266 instances (Table 3); most were ACB 1 medications 
(52·1%) with 36·3% ACB3 drugs. 
 
Antipsychotics comprised 35.4% of the total cumulative ACB score, followed by anticholinergics (16%) (ATC 
N04A e.g. biperiden) (figure 1). Of those with antipsychotics (319), 25% (n=82) received two or more 
concurrently.  
 Medications with ACB score 2 were reported by 26·6% of those with exposure, with carbamazepine being the 
most frequent (n=127). ACB score 3 medicines were reported by 59·1% (n=309), with olanzapine the most 
frequent (n=101). Antipsychotics accounted for 46% of ACB 3 medicines, N04A anticholinergics (27·6%) and 
antidepressants (9·4%).  
Of those who reported N04A anticholinergics (n=121), 91·7% reported concurrent use of antipsychotics with 
anticholinergic properties and of those receiving antipsychotics (319), 35·2% also received N04A anticholinergic 
agents, and of those with antipsychotic polytherapy (n=82), over half (58·5%, n=48) received a N04A 
anticholinergic. 
INSERT TABLE 3, FIGURE 2 HERE 
 
 
Those aged over 65 years were more likely to report an ACB score of 1-4 (odds ratio [OR] 3·28, 95% CI 1·49-
7·28) and ACB of 5+ ( [OR] 3·08, 95% CI 1·20-7·63), after controlling for other factors (Table 4). Having a 
mental health condition was associated with having a score of ACB 1-4 ([OR] 9·79, 95% CI 5·63-17·02), and 
ACB 5+ ([OR] 23·74, 95% CI 12·29-45·83). Levels of ID, gender or place of residence were not significant with 
either level of AC exposure, nor were the other clinical conditions. 
 
INSERT TABLE 4 HERE 
Day time drowsiness  was significantly associated with a higher ACB score at univariate level (p<0·001), with 
43·3% of those with an ACB score of 5+ reporting a moderate/high likelihood of daytime drowsiness, compared 
to 23·4% of those with no anticholinergic exposure (Table 5). A greater proportion of those with higher 
anticholinergic burden reported a doctor’s diagnosis of chronic constipation; 26·6% of those with an ACB score 
of 5+ compared to 7·5% of those with no AC exposure (p<0·001). Furthermore, 29·0% of those with an ACB 5+ 
used two or more concurrent laxatives, compared to 4·7% of those with no exposure (p<0·001). 
INSERT TABLE 5 HERE 
 
 
 
Discussion  
 
Principal Findings 
As the first study in a representative population of older adults with ID, our findings reveal high levels of 
cumulative anticholinergic exposure, with 30% exposed to an ACB score of 5+. Multivariable regression analysis 
showed that those over 65 years and those with mental health conditions were much more likely to have high 
anticholinergic exposure. Antipsychotics, N04A anticholinergics, antiepileptics and antidepressants were the most 
frequent classes contributing to the ACB. Antipsychotics accounted for over one-third of the cumulative burden, 
with a notably high prevalence of typical antipsychotics and with one in four of these taking two or more 
antipsychotics. Our findings revealed that higher anticholinergic burden was associated with greater likelihood of 
reporting daytime dozing, constipation and use of multiple laxatives. 
 
Comparison with other studies 
There are no equivalent studies with other cohorts with ID. In studies that used the ACB scale with cohorts of 
older adults without ID, the degree of the anticholinergic burden found in our study was much greater and the 
types of anticholinergic drugs were different. (20, 33, 34) (Table 6). 
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Factors associated with Anticholinergic Burden and Adverse effects 
 
 
Our analysis showed no association between higher anticholinergic burden scores and gender, but age over 65 
years was a significant factor both for exposure to a score of 1-4 and exposure to an ACB score of 5 or more 
(Table 4). After adjusting for relevant confounders, we did not find an association between the level of ID and 
anticholinergic burden, however it was notable that 85% of those with severe or profound ID were exposed to 
anticholinergic medications, and over one-third to an ACB score of 5+. The confidence intervals across all the 
categories were quite wide indicating the scale of variation remaining after adjusting for confounding factors, 
including polypharmacy. Other studies have only examined psychotropic polypharmacy (35, 36) or polypharmacy 
(37) and have reported varying associations with age, gender and level of ID, but in contrast to the general elderly 
population, where women are identified as being more likely to be exposed to psychotropic polypharmacy. (38).  
It may be that many of the conditions that are treated with AC medicines occur earlier in the lives of people with 
ID than in those without ID so that the use of these medicines has become similar in men and women and is 
increasing to a lesser extent in these older age groups. 
 
 
Almost half of those with a mental health condition andfour in ten of those over 65 were exposed to an ACB of 
5+. The wide confidence intervals of the association of mental health conditions may reflect variability in 
reporting of mental health conditions, however, 12 of the 16 highest contributors to the ACB score were drugs for 
mental health.  
 
We found that 35% of those with antipsychotics had concurrent exposure to N04A anticholinergics, which was 
higher than previously reported in a UK study (14%) (39), yet Parkinson’s disease was reported by only 1% in 
this cohort. The risks associated with using these medicines in combination in patients who are vulnerable and 
cognitively impaired are substantial (40). Our findings revealed that over one-fifth of those reporting 
antipsychotics reported chlorpromazine and 14% reported haloperidol, both agents that carry significant 
anticholinergic, noradrenergic and antihistamine adverse effects (41). These older agents are associated with more 
extra-pyramidal side effects (41) and people with ID may be more susceptible to these side effects compared to 
the general population (17, 41) Risperidone was also the second most commonly antipsychotic, an agent  also 
associated with extra-pyrimidal side effects 41)While our findings are limited by the fact that we did not have 
information in relation to side effects of medications, it is probable that these anticholinergic agents are being to 
some extent used to treat or in prophylaxis of extra-pyramidal symptoms associated with antipsychotic agents. 
There is recent evidence of increased incident dementia associated with higher anticholinergic burden and length 
of exposure in those over 65 years.(7)  
 
Our univariate findings must be interpreted conservatively; while a higher AC burden was associated with a risk 
of daytime dozing, falls in the previous year were not significantly associated, in contrast to studies in the general 
older population.(6, 42) Constipation is common in older people, and increases with age.(43) People with ID are 
at risk of constipation from several factors,(44) and we found an association between increasing anticholinergic 
burden and constipation and laxative use, and furthermore, with six times as many of those with ACB 5+ receiving 
laxative polytherapy as those with no AC exposure. Multiple laxative use poses risks of electrolyte disturbance 
and dehydration which may exacerbate constipation.(43) The relationship between anticholinergic medications 
and xerostomia and tooth loss has been previously established (45) but although a higher proportion of the 
participants with an ACB of 5+ were edentate (30·6%), this was not significant. 
Impact of Findings on Practice 
Since anticholinergic activity may affect both central and peripheral systems, several factors make managing the 
anticholinergic burden complex in people with ID; 
Multimorbidity combined with complex mental health conditions and epilepsy increases the number and 
different classes of drugs with anticholinergic activity prescribed for people with ID, and the cumulative burden.  
The sensitivity of people with ID to the effects of these drugs may be greater, and may increase with age, but is 
unquantifiable because of lack of evidence. Consequently, the prevalence of anticholinergic side effects may be 
greater in this population, especially as the oldest age group were exposed to the greatest burden. 
Patient assessment is challenging, which may lead to diagnostic overshadowing (14) and initiation of 
inappropriate drugs. Physical problems, such as constipation, may present as challenging behaviours (41), which 
could trigger a prescribing cascade with a significant anticholinergic burden, as the association of antipsychotic, 
anticholinergic and laxative use in this study suggests. 
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A high proportion of people with ID are prescribed drugs with anticholinergic effects from an early age, and are 
likely to be exposed for many years(17). Length of exposure may increase as life expectancy of people with ID 
grows, potentially increasing the risks of chronic use of psychotropics (46). 
These factors imply that the extent and burden of anticholinergic side effects in people with ID are greater than 
in the general older population, and could have an impact on their quality of life. Therefore, assessment of this 
burden, particularly among the oldest and those with mental health conditions and multiple morbidities, and who 
receive psychotropic polypharmacy is essential. 
 
The risks of cumulative anticholinergic burden could be reduced through regular, multidisciplinary medication 
review. Scales such as the ACB scale, allied to review of patients symptoms currently remain useful aids to guide 
clinical decision making (47). Little is known about the influence of ageing on people with ID and their response 
to medicines, which reinforces the need for review and education of healthcare professionals. Integrated and co-
ordinated care is receiving increased attention in the older population (48), and needs to be further developed 
when providing care to people with ID. In older people and those with cognitive impairment, anticholinergic-
induced cognitive impairment is more likely to occur at therapeutic doses potentially increasing risks of 
medication errors (49) for people with ID managing their own medicines. Continuing deinstitutionalisation creates 
challenges for Primary Care professionals who may not have the necessary expertise or experience to provide care 
for people with ID, nor may they be able to meet the needs of their carers (50). Guidelines are needed to support 
professionals, people with ID and carers to optimise anticholinergic medicines use. However, since people with 
ID are often excluded from RCTs (51), additional data may also need to be generated by national audits and 
longitudinal studies(14). 
 
Strengths and Limitations 
Our study has four important strengths. First, use of a large, randomly selected population-representative sample 
offered sufficient power for multivariate analysis, with findings generalisable to the population with ID in Ireland. 
Second, the great majority of respondents recorded detailed medication data, including over-the-counter 
medicines (98%). Third, participants and/or proxy respondents underwent a detailed assessment of health 
characteristics, providing data on potential confounders for the regression model. The use of the Bonferroni 
correction addressed the problem of multiplicity. Fourth, we used the ACB scale, which has been widely used, 
making the assessment of anticholinergic burden robust and relevant to clinical practice (3, 20). We added to its 
content validity by reviewing other anticholinergic medicines available in Ireland with an independent expert. 
There are also limitations; there was no independent confirmation of medicines or conditions, but cross-checking 
of medicines in the pre-interview questionnaire at the time of interview improved accuracy. Information was also 
not recorded about disease severity. Data on dose and frequency of medicines were not always available and 
adverse effects may be dose dependent (47), however the ACB scale does not take dose into account. While a 
higher dose of an anticholinergic agent would be expected to cause more central effects, the relationship may not 
be linear(53). The ACB scale has not been validated against measures of in vitro anticholinergic activity. However, 
assays are difficult to interpret, not readily available in practice and due to variations in blood-brain barrier 
permeability may not reflect levels in the CNS. It is currently accepted, that allied to a careful review of the 
patients’ symptoms and medicines, scales and lists such as the ACB scale remain the best aid to guide clinical 
decision making (47).The ACB scale does not take into account influences of patient variability in drug response 
associated with older age, frailty, multimorbidity, cognitive reserve and individual pharmacokinetic factors. 
As an observational study, we could only describe associations between anticholinergic burden and clinical and 
demographic factors. In our multivariate analysis, potential bias was reduced by adjusting for known confounders; 
however, residual confounding may remain. Although potential adverse effects associated with anticholinergic 
exposure were examined at univariate level, other factors such as functional status, or baseline cognitive status 
which could influence the prescription of anticholinergics were not measured in this study, and this analysis was 
descriptive and not adjusted for confounders. 
 
 
 
In conclusion, the use of medications with anticholinergic activity is commonplace among older adults with ID, 
with psychotropic agents accounting for much of the burden. For the first time in people with ID a high 
anticholinergic burden has been shown to be associated with daytime dozing, constipation and multiple laxative 
use. The possible impact that anticholinergics may have on cognitive and executive function should be evaluated 
and more attention should be paid to the assessment of peripheral anticholinergic effects, such as constipation. 
People with ID are amongst the most vulnerable members of society and regular, multidisciplinary review of 
medications to decrease the use of anticholinergic medicines is likely to reduce morbidity and improve quality of 
life in this population. 
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Table 1 Anticholinergic exposure binary table 
 Total 
Population 
(n=736) 
Anticholinergic 
Use  
(n=522) 
No 
anticholinergic 
use  
(n=214) 
 
p-value† 
 
Sex 
    
Male 330(44·8) 225 (68·2) 105 (31·8) 0·08 
Female 406(55·2) 297 (73·2) 109 (26·8)  
     
Age      
40-49 years 266 (36·1) 171 (64·3) 95 (35·7) <0·001 
50-64 years 336 (45·6) 234 (69·6) 102 (30·4)  
65+ years 134 (18·2) 117 (87·3) 17 (12·7)  
     
Level of ID (n=682)*     
Mild  163 (23·9) 107 (65·6) 56 (34·4)  
 Moderate 316 (42·9) 207 (65·5) 106 (34·5) <0·001 
Severe/ profound 203 (27·6) 173 (85·2) 30 (14·8)  
     
Residential Setting     
Independent 122 (16·6) 47 (38·5) 75 (61·5) <0·001 
Community Group 
Home 
265 (36·0) 183 (69·1) 82 (30·9)  
Residential 349 (47·4) 292 (83·7) 57 (16·3)  
     
Polypharmacy 
Status 
    
No- polypharmacy 341 (46·3) 160 (46·9) 181 (53·1) <0.001 
Polypharmacy 395 (53·7) 362 (91·6) 33 (8·4)  
Number of co-
morbidities 
    
0 51 27 (52·9) 24 (47·1) <0·001 
1 157 84 (53·5) 73 (46·5)  
2 192 137 (71·4) 55 (28·6)  
3+ 336 279 (83·0) 57 (17·0)  
     
Data are n(%) * 54 Level of ID not verified  
p<0·05 is significant 
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Table 2 Demographic and Clinical Characteristics by ACB Score Categories  
Characteristic Total 
Population 
 
(n=736) 
No- 
anticholinergic 
exposure 
(n=214) 
ACB 1-4 
 
 
(n=308) 
ACB 5+ 
 
 
(n=214) 
 
p-value* 
      
Demographics      
Gender       
Male 330 (44·8) 105 (31·8) 119 (36·1) 106 (32·1) 0·013 
Female 406 (55·2) 109 (26·8) 189 (46·6) 108 (26·6)  
Age group       
40-49 years 266 (36·1) 95 (35·7) 103 (38·7) 68 (25·6) <0·001 
50-64 years 336 (45·6) 102 (30·4) 143 (42·6) 91 (27·1)  
65+ years 134 (18·2) 17 (12·7) 62 (45·5) 55 (41·8)  
Level of ID †      
Mild  163 (23·9) 56 (34·4) 66 (23·2) 41 (19·9) <0·001 
Moderate 316 (42·9) 109 (34·5) 
30 (14·8) 
118 (37·3) 89 (28·2)  
Severe/profound 203 (27·6) 99 (48·8) 74 (36·5)  
Residential setting      
Independent 122 (16·6) 75 (61·5) 36 (29·5) 11 (9·0) <0·001 
Community Group 
Home 
 
265 (36·0) 
 
82 (30·9) 
 
124 (46·4) 
 
59 (22·6) 
 
Residential 349 (47·4) 57 (16·3) 148 (42·4) 144 (41·3)  
      
Polypharmacy 
Status 
     
No-polypharmacy  
341 (46·3) 
 
181 (53·1) 
 
138 (38·1) 
 
22 (6·7) 
 
<0·001 
Polypharmacy (5+ 
medicines) 
395 (53·7) 33 (8·4) 170 (43·0) 192 (48·6)  
      
Conditions      
Eye disease 380 (51·6) 128 (33·7) 157 (41·3) 95 (25·0) <0·001 
Mental Health‡ 356 (50·4) 22 (6·2) 168 (47·2) 166 (46·6) <0·001 
Neurological ** 268 (36·4) 53 (19·8) 132 (49·3) 83 (31·0) <0·001 
Gastrointestinal 198 (26·9) 32 (16·2) 88 (44·4) 78 (39·4) <0·001 
Endocrine 162 (22·0) 49 (30·3) 67 (40·7) 46 (28·4) 0·94 
Joint Disease 153 (20·8) 36 (23·5) 71 (46ҟ4) 47 (29·0) 0·21 
Hypertension 112 (15·2) 26 (12·4) 43 (38·4) 46 (30·1) 0·06 
Heart Disease 89 (12·1) 22 (24·7) 42 (47·2) 21 (38·9) 0·49 
 
 
Data are n(%). *From χ2 test. †54 Level of ID not verified.  ‡ 30 Don’t know/missing data.  
**Neurological disease includes epilepsy, cerebral palsy,multiple sclerosis,Parkinson’s disease, 
Spina bifida,muscular dystrophy, Alzheimer’s disease, dementia, organic brain syndrome or senility and serious 
memory impairment 
p<0·10 is significant for entry into multinomial logistic regression 
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Table 3 Frequently Reported ACB Medicines by those with AC exposure (N=522) 
Medicine (ATC Code) Type  N (%) Rank  
ACB 3    
Olanzapine (N05AH03) Atypical antipsychotic 101 (19·3) 3 
Biperiden (N04AA02) Anticholinergic 85(16·3) 4 
Chlorpromazine (N05AA01) Typical antipsychotic 70 (13·4) 6 
Haloperidol (N05AD01) Typical antipsychotic 44 (8·4) 8 
Procyclidine (N04AA04) Anticholinergic 37(7·0) 9 
Quetiapine (N05AH05) Atypical antipsychotic 27 (5·1) 12 
Paroxetine (N06AB05) SSRI antidepressant 25 (4·8) 14 
    
ACB 2    
Carbamazepine (N03AF01) Mood-stabilising antiepileptic 127(24·3) 1 
    
ACB 1     
Risperidone (N05AX08) Atypical antipsychotic 111(21·4) 2 
Diazepam* (N05BA01) Benzodiazepine anxiolytic 82(15·7) 5 
Loperamide (A07DA03) Anti-diarrhoeal 56(10·7) 7 
Escitalopram (N06AB10)  SSRI antidepressant 35(6·8) 9 
Furosemide (CA03CA01/ 
C03DB01) 
Diuretic 33(6·3) 10 
Ipatropium (R03BB01)  Inhaled anticholinergic 31(5·9) 11 
Citalopram (N06AB04) SSRI antidepressant 25(4·8) 13 
Alprazolam (N05BA12) Benzodiazepine anxiolytic 22(4·2) 15 
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Table 4 Multivariate Analysis of Factors associated with ACB score 1-4 and ACB score 5+ (n=658) 
 ACB Categories 
 ACB score 1-4 
 
ACB score 5+ 
Characteristic 
 
OR (95% CI) P-Value OR (95% CI) P-Value 
Gender 
Male 
Female 
1 (reference) 
1·34 (0·84-2·15) 
0·22 1 (reference) 
0·74 (0·41-1·31) 
0·31 
Age 
40-49 years 1 (reference)  1 (reference)  
50-64 years 1·13 (0·69-1·85) 0·64 0·97 (0·52-1·79) 0·91 
65+ years 3·28 (1·49-7·25) 0·003 3·08 (1·2-7·63) 0·02 
Level of ID* 
Mild  1 (reference)  1 (reference)  
Moderate   0·78(0·45-1·37) 0·39  0·66 (0·33-1·36) 0·26 
Severe/ profound 1·44 (0·67-3·09) 0·35 0·83 (0·33-2·07) 0·68 
Residence 
Independent/Community Group 
Home 
 
1 (reference) 
  
1 (reference) 
 
Residential 0·92 (0·53-1·58) 0·75 1·56 (0·82-2·97) 0·18 
 
Conditions 
    
Mental Health† 
No 1 (reference)  1 (reference)  
Yes 9·79(5·63-17·02) <0·001 23·74(12·29-45·83) <0·001 
Neurological 
No 1 (reference)  1 (reference)  
Yes 1·30 (0·76-2·20) 0·34 0·73 (0·39-1·37) 0·33 
Gastrointestinal 
No 1 (reference)  1 (reference)  
Yes 1·21 (0·66-2·22) 0·54 1·27 (0·64-2·53) 0·52 
Eye     
No 1 (reference)  1 (reference)  
Yes 0·81 (0·50-1·32) 0·41 0·68 (0·37-1·24) 0·21 
Hypertension 
No 1 (reference)  1 (reference)  
Yes 0·66 (0·32-1·35) 0·25 0·74 (0·32-1·70) 0·48 
 
 
Reference category = ACB 0, p<0·05 is significant, all significant factors in bold 
Cox and Snell  R2 = 0.46 Nagelkirke R2 = 0·52 
Data are adjusted odds ratio (OR).  Model is adjusted for polypharmacy status. 
*54 no verified level of ID. †30 missing data/ don’t know 
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Table 5 ACB Scores and Adverse Effects 
Characteristic Total 
Population 
(n=736) 
No AC 
Exposure 
(n=214) 
 
ACB 1-4 
(n=308) 
 
ACB 5+ 
(n=214) 
 
p-value* 
      
Central Anticholinergic Adverse 
Effects 
     
Likelihood of Daytime Dozing      
High/ Moderate Likelihood 267 (36·3) 50(23·4) 118(38·3) 99(46·3) <0·001 
Slight/ Would never doze 469 (63·7) 164(76·6) 190(61·7) 115(53·7)  
Have fallen in previous year † 200(27·4) 
 
43(20·3) 95(31·0) 62(29·1) 0·02 
Peripheral Adverse Effects      
“Is constipation a problem for you?” ‡ 316(43·6) 60(28·7) 139(45·7) 117(55·2) <0·001 
Doctor’s Diagnosis of Chronic 
Constipation  
128(17·4) 16(7·5) 55(17·9) 57(26·6) <0·001 
Any Laxative Use 276(37·5) 41(19·2) 119(38·6) 116(53·5) <0·001 
1 Laxative 146(19·8) 31 (14·5) 61(19·8) 54(25·2)  
2+ Laxatives 130(17·7) 10 (4·7) 58(18·8) 62(29·0)  
Dentate Status¥      
Dentate 547(74·5) 169(80·5) 228(74·0) 150(69·4) 0·03 
Edentulous 187(25·5) 41(18·5) 80(26·0) 66(30·6)  
      
 
Data are n(%)  * From χ2 test (and applying Bonferroni correction), p <0·008 for significance.  †5 missing data ‡ 
11 missing data. ¥2 missing data 
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Table 6: Study Comparisons 
Study Population ACB 1 
medicines 
ACB 2-3 
medicines 
ACB score 
5+ 
Rank order of most frequent 
AC medicines ( with 
corresponding ACB scores) 
 
Present Study (2015) 
 
736 people with ID 
aged 41-90 years 
 
70% had an 
ACB  score 
of 1+ 
 
50% had a 
definite AC 
medicine 
 
29% had an 
ACB score 5+ 
 
1.Carbamazepine(2) 
2.Risperidone(1) 
3.Olanzapine(3) 
4.Biperiden(3) 
 
 
Use of medications 
with anti-cholinergic 
activity and injurious 
falls in community-
dwelling adults aged 
50 years and older 
Richardson et al.  
(2015)  
 
 
6,666 Irish 
community dwelling 
adults over 50 years 
 
26% had an 
ACB 1 
medicine 
 
4% had a 
definite AC 
medicine 
 
Not reported 
 
1.Hydrochlorothiazide(1) 
2.Atenolol(1) 
3.Bendroflumethiazide(1) 
 
Anticholinergic 
medication use and 
cognitive impairment 
in the older 
population: the 
medical research 
council cognitive 
function and ageing 
study  
Fox et al.(2011) 
 
 
12,423 community 
and institutional 
dwelling adults aged 
65 years and older in 
England and Wales 
 
48% had an 
ACB score of 
1+ 
 
4% had 
medicines 
with definite 
AC activity 
 
2% had an 
ACB score 5+ 
 
1.Furosemide(1) 
2.Dextroproxyphene(1) 
3.Atenolol(1),  
4.Nifedipine(1) 
 
Total anticholinergic 
burden and risk of 
mortality and 
cardiovascular 
disease over 10 years 
in 21,636 middle-aged 
and older men and 
women of EPIC-
Norfolk prospective 
population study  
Myint et al 
(2014) 
 
 
21, 636 adults aged 
40-79 years from 
general practice 
registers in England 
 
12.5% had an 
ACB score of 
1 
 
6.1% of the 
population 
had a score of 
2-3 
 
1.3% had a 
score of ACB 
3+ 
 
Not reported 
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Figure 1 Flow Chart 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
736 participants with medication data for 
univariate descriptive anticholinergic burden 
analysis 
78 participants excluded because 
No verified level of ID= 54, and 
missing answer in mental health 
condition = 30 
 
658 participants with data for multivariate logistic 
regression 
Inclusion Criteria for IDS-TILDA Study: registered on the Irish 
National Intellectual Disability Database (NIDD), aged over 40 
years 
1800 Patient Identifier Numbers (PINs) randomly selected 
from the NIDD and invited to partake in the study 
753 participants aged 41-90 years consented and 
recruited 
Random Representativeness (RR) =46%, 
representing 8.9% of the population on the NIDD 
aged over 40 
17 participants excluded because of 
missing medication data 
753 participants and/or carers completed Pre-
Interview Questionnaire and Face-to-Face 
Interview (included demographic, clinical and 
medication information) 
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Figure 2 Contribution of therapeutic classes to Total ACB Score in the Population 
Figure adapted from Lancot et al. (55) 
* The Contribution of Each Medication Class was Estimated from the Number of People Reporting Use of Medications of that Class Multiplied 
by its score (1-3) on the Anticholinergic Cognitive Burden (ACB) Scale,Divided by the Population Cumulative ACB Score 
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